PT3600281T - Terapia combinada para o tratamento ou prevenção de tumores - Google Patents

Terapia combinada para o tratamento ou prevenção de tumores

Info

Publication number
PT3600281T
PT3600281T PT187708128T PT18770812T PT3600281T PT 3600281 T PT3600281 T PT 3600281T PT 187708128 T PT187708128 T PT 187708128T PT 18770812 T PT18770812 T PT 18770812T PT 3600281 T PT3600281 T PT 3600281T
Authority
PT
Portugal
Prior art keywords
tumours
prevention
treatment
combination therapy
therapy
Prior art date
Application number
PT187708128T
Other languages
English (en)
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of PT3600281T publication Critical patent/PT3600281T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT187708128T 2017-03-23 2018-03-23 Terapia combinada para o tratamento ou prevenção de tumores PT3600281T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy

Publications (1)

Publication Number Publication Date
PT3600281T true PT3600281T (pt) 2023-09-04

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187708128T PT3600281T (pt) 2017-03-23 2018-03-23 Terapia combinada para o tratamento ou prevenção de tumores

Country Status (28)

Country Link
US (1) US11213506B2 (pt)
EP (1) EP3600281B1 (pt)
JP (1) JP6905075B2 (pt)
KR (1) KR102228055B1 (pt)
CN (1) CN110461324A (pt)
AU (1) AU2018238202B2 (pt)
BR (1) BR112019019748A2 (pt)
CA (1) CA3056685C (pt)
DK (1) DK3600281T3 (pt)
EA (1) EA201992220A1 (pt)
ES (1) ES2953575T3 (pt)
FI (1) FI3600281T3 (pt)
HR (1) HRP20230936T1 (pt)
HU (1) HUE063299T2 (pt)
IL (1) IL269522B2 (pt)
LT (1) LT3600281T (pt)
MX (1) MX2019011221A (pt)
MY (1) MY197427A (pt)
NZ (1) NZ756754A (pt)
PH (1) PH12019502132A1 (pt)
PL (1) PL3600281T3 (pt)
PT (1) PT3600281T (pt)
RS (1) RS64472B1 (pt)
SG (1) SG11201907891XA (pt)
SI (1) SI3600281T1 (pt)
UA (1) UA125614C2 (pt)
WO (1) WO2018170559A1 (pt)
ZA (1) ZA201906001B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634469C (en) * 2005-12-23 2012-08-21 Qbiotics Limited Tiglien-3-one derivatives
JP6656733B2 (ja) 2013-08-05 2020-03-04 ツイスト バイオサイエンス コーポレーション 新規合成した遺伝子ライブラリ
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
JP6982362B2 (ja) 2015-09-18 2021-12-17 ツイスト バイオサイエンス コーポレーション オリゴ核酸変異体ライブラリーとその合成
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
KR102217487B1 (ko) 2016-09-21 2021-02-23 트위스트 바이오사이언스 코포레이션 핵산 기반 데이터 저장
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CA3066744A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
SG11202002194UA (en) 2017-09-11 2020-04-29 Twist Bioscience Corp Gpcr binding proteins and synthesis thereof
WO2019079769A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES
WO2019222706A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
SG11202110599RA (en) * 2019-04-12 2021-10-28 QBiotics Pty Ltd Method of treating tumours
EP3986394A4 (en) * 2019-06-19 2022-08-10 QBiotics Pty Ltd BIOFILM INTERRUPTION
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
IL293670A (en) * 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
KR20220151333A (ko) 2021-05-06 2022-11-15 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
WO2023115123A1 (en) * 2021-12-21 2023-06-29 QBiotics Pty Ltd Crystalline intermediates
WO2023154984A1 (en) * 2022-02-17 2023-08-24 QBiotics Pty Ltd Combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022103B2 (en) * 2005-07-13 2011-09-20 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
CA2634469C (en) * 2005-12-23 2012-08-21 Qbiotics Limited Tiglien-3-one derivatives
HUE043272T2 (hu) * 2013-04-18 2019-08-28 Qbiotics Ltd Eljárások és készítmények sebgyógyuláshoz
WO2015133596A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 細胞培養用組成物
EP3169340B1 (en) 2014-07-16 2020-09-02 Institut Gustave Roussy Combination of oncolytic virus with immune checkpoint modulators
EP3204040B1 (en) 2014-10-10 2021-12-08 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
CN104926758A (zh) * 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用
EP3331851A1 (en) * 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof

Also Published As

Publication number Publication date
BR112019019748A2 (pt) 2020-04-14
AU2018238202A1 (en) 2019-09-19
HRP20230936T1 (hr) 2023-11-24
JP2020511512A (ja) 2020-04-16
SG11201907891XA (en) 2019-09-27
EP3600281A1 (en) 2020-02-05
EP3600281B1 (en) 2023-05-31
CA3056685A1 (en) 2018-09-27
IL269522B2 (en) 2024-05-01
PL3600281T3 (pl) 2023-09-11
WO2018170559A1 (en) 2018-09-27
HUE063299T2 (hu) 2024-01-28
US20200030279A1 (en) 2020-01-30
CN110461324A (zh) 2019-11-15
IL269522A (pt) 2019-11-28
AU2018238202A8 (en) 2024-03-28
UA125614C2 (uk) 2022-05-04
MX2019011221A (es) 2019-11-01
NZ756754A (en) 2024-02-23
EA201992220A1 (ru) 2020-02-11
LT3600281T (lt) 2023-09-11
AU2018238202B2 (en) 2024-03-28
RS64472B1 (sr) 2023-09-29
SI3600281T1 (sl) 2023-10-30
KR102228055B1 (ko) 2021-03-16
JP6905075B2 (ja) 2021-07-21
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
KR20190126431A (ko) 2019-11-11
ES2953575T3 (es) 2023-11-14
US11213506B2 (en) 2022-01-04
EP3600281A4 (en) 2020-03-18
CA3056685C (en) 2024-01-16
MY197427A (en) 2023-06-16
ZA201906001B (en) 2023-12-20
FI3600281T3 (fi) 2023-08-24
PH12019502132A1 (en) 2020-07-06

Similar Documents

Publication Publication Date Title
SI3600281T1 (sl) Kombinirana terapija za zdravljenje ali preprečevanje tumorjev
IL291844B1 (en) smc combined therapy for cancer treatment
IL290149A (en) Combined treatment for cancer
HK1247129A1 (zh) 治療癌症的聯合療法
IL267795A (en) Combined treatment for cancer
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL276398A (en) Combined treatment for mastocytosis
IL280337A (en) LAG-3 combination therapy for cancer treatment
IL281845A (en) Combined treatment for cancer
IL264589A (en) Combined treatment for pancreatic cancer
IL284162A (en) Integrated healing for cancer treatment
IL269357A (en) Combined therapies for the treatment of breast cancer
IL266993A (en) Combined therapy for cancer treatment
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL273835A (en) Combined product for cancer treatment
IL253642A0 (en) Combined treatment for cancer
EP3603635A4 (en) USE OF MELATONIN FOR TREATMENT OF TUMORS
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
PL3319638T3 (pl) Kompozycja zawierająca cyneol do leczenia chorób nowotworowych i/lub raków
IL281782A (en) Drug combination for cancer treatment
GB201704474D0 (en) Combination therapy for treatment of cancer
GB201700502D0 (en) Treatment of tumours of the central nervous system